Nuvation Bio Inc (NYSE:NUVB)’s traded shares stood at 0.85 million during the last session, with the company’s beta value hitting 1.35. At the close of trading, the stock’s price was $2.41, to imply an increase of 2.99% or $0.07 in intraday trading. The NUVB share’s 52-week high remains $4.16, putting it -72.61% down since that peak but still an impressive 60.58% since price per share fell to its 52-week low of $0.95. The company has a valuation of $806.82M, with an average of 1.85 million shares in intraday trading volume over the past 10 days and average of 1.54 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Nuvation Bio Inc (NUVB), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give NUVB a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.14.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nuvation Bio Inc (NYSE:NUVB) trade information
After registering a 2.99% upside in the last session, Nuvation Bio Inc (NUVB) has traded red over the past five days. The 5-day price performance for the stock is 0.84%, and -16.32% over 30 days. With these gigs, the year-to-date price performance is 59.60%. Short interest in Nuvation Bio Inc (NYSE:NUVB) saw shorts transact 20.23 million shares and set a 14.52 days time to cover.
The extremes give us $5 and $10 for target low and target high price respectively. As such, NUVB has been trading -314.94% off suggested target high and -107.47% from its likely low.
Nuvation Bio Inc (NUVB) estimates and forecasts
Looking at statistics comparing Nuvation Bio Inc share performance against respective industry, we note that the company has underperformed competitors. Nuvation Bio Inc (NUVB) shares are -26.75% down over the last 6 months, with its year-to-date growth rate lower than industry average at -522.86% against 17.60%. Revenue is forecast to shrink -55.60% this quarter before falling -133.30% for the next one.
NUVB Dividends
Nuvation Bio Inc has its next earnings report out on 2024-Oct-31. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
Nuvation Bio Inc insiders hold 27.01% of total outstanding shares, with institutional holders owning 44.64% of the shares at 61.16% float percentage. In total, 44.64% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 28.82 million shares (or 13.1578% of shares), all amounting to roughly $84.16 million.
The next major institution holding the largest number of shares is ECOR1 CAPITAL, LLC with 19.21 million shares, or about 8.7696% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $56.09 million.
